Haleon plc: 2025 Q3 Trading Statement
30 October 2025: Haleon plc (the "Company" or "Haleon") today announces its Q3 trading statement for the year ending 31 December 2025 is available at: http://www.rns-pdf.londonstockexchange.com/rns/4049F_1-2025-10-29.pdf.
The Q3 trading statement will also be available on the Haleon website www.haleon.com/investors, and has been submitted in full unedited text to the Financial Conduct Authority's National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Presentation for analysts and shareholders
A short presentation followed by Q&A will be hosted by Dawn Allen, Chief Financial Officer at 9:00am GMT (10:00am CET) on 30 October 2025, which can be accessed at www.haleon.com/investors.
For analysts and shareholders wishing to ask questions on the Q&A call, please use the dial-in details below which will have a Q&A facility:
|
UK:
|
+44 (0) 808 189 0158
|
|
US:
|
+1 855 979 6654
|
|
All other:
|
+44 (0) 203 936 2999
|
|
Passcode:
|
407228
|
An archived webcast of the Q&A call will be available later on the day of the results and can be accessed at www.haleon.com/investors.
Amanda Mellor
Company Secretary
Enquiries
|
Investors
|
Media
|
|
Jo Russell
|
+44 7787 392441
|
Zoë Bird
|
+44 7736 746167
|
|
Rakesh Patel
|
+44 7552 484646
|
Victoria Durman
|
+44 7894 505730
|
|
Email: [email protected]
|
Email: [email protected]
|
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
For more information please visit www.haleon.com.